The effect of the co-administration of atazanavir (ATV) and ritonavir (RTV) on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female subjects.

Trial Profile

The effect of the co-administration of atazanavir (ATV) and ritonavir (RTV) on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2011

At a glance

  • Drugs Atazanavir (Primary) ; Ethinylestradiol/norgestimate; Ritonavir
  • Indications HIV infections; Pregnancy
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Apr 2011 Actual end date (1 Nov 2006) added as reported by ClinicalTrials.gov.
    • 30 Oct 2007 Status changed from in progress to completed.
    • 13 Mar 2007 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top